Update on JNK inhibitor patents: 2015 to present-Reference-Cited by-同舟云学术

Update on JNK inhibitor patents: 2015 to present

Published:2024-09-08 Issue: Volume: Page:1-21
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Feng Guotai,Yang Xiao,Shuai Wen,Wang Guan¹,Ouyang Liang¹

Affiliation:

1. Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, National Clinical Research Center for Geriatrics, West China Hospital, and West China second Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Sichuan Province

Postdoctoral Fellowship Program of CPSF

Postdoctor Research Fund of West China Hospital, Sichuan University

China Postdoctoral Science Foundation funded project

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2024.2400167

Reference121 articles.

1. Signal Transduction by the JNK Group of MAP Kinases

2. Activation of the JNK signaling pathway: Breaking the brake on apoptosis

3. Mammalian MAP kinase signalling cascades

4. The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases

5. BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G 2 /M

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting JNK kinase inhibitors via molecular docking: A promising strategy to address tumorigenesis and drug resistance;Bioorganic Chemistry;2024-12